康恩贝 (600572.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.2x

Market Cap

CNY 10.69B

MomentumView details →

1D Return

−2.55%

YTD Return

−1.57%

RSI (14)

48.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.2x

Market Cap

CNY 10.69B

RSI (14)

48.8

MomentumView details →

1D Return

−2.55%

YTD Return

−1.57%

ProfitabilityView details →

Gross Margin

53.91%

Net Margin

7.22%

EBITDA Margin

15.29%

ROE (TTM)

6.66%

ROA (TTM)

4.73%

Asset Turnover

0.66x

GrowthView details →

Revenue YoY

+4.99%

EPS YoY

−19.76%

FCF YoY

+17.21%

Revenue CAGR 3Y

+2.56%

EPS CAGR 3Y

+10.72%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.07

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

1.98x

Quick Ratio

1.54x

Div Yield

3.42%

Div Rate

CNY 0.15

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

6.69B

Net Income (TTM)

483.42M

Op. CF (TTM)

1.01B

Latest newsMore news →

Conba Group's wholly-owned subsidiary Inner Mongolia Conba received clinical trial approval from the National Medical Products Administration for a new indication of Shexiang Tongxin Dropping Pills.43d ago

Similar companies

羚锐制药600285.SH 国药现代600420.SH Dr. Reddy's Laboratories LimitedRDY 微芯生物688321.SH Ab&B Bio Tech Co Ltd.02627.HK Consun Pharmaceutical Group Limited01681.HK Find similar companies →

Latest newsMore news →

Conba Group's wholly-owned subsidiary Inner Mongolia Conba received clinical trial approval from the National Medical Products Administration for a new indication of Shexiang Tongxin Dropping Pills.43d ago